← Explore

ClinTrialFinder buyers: prospects (?)

Likely buyers (individuals and small teams) in the US, UK, EU and India who would plausibly buy a software product like ClinTrialFinder (https://www.clintrialfinder.info/). What the product says about itself (public site): Maker launch on TinyLaunch: AI-powered clinical trial matching. Paste your medical history, and AI analyzes thousands of trials from ClinicalTrials.gov to find eligible matches,… Site: ClinTrialFinder - AI-Powered Clinical Trial Matching | Paste your medical summary and get clinical trials ranked by relevance with evidence — not just eligibility. AI-powered matching, no login required. Results in minutes. | Paste a patient description, get ranked clinical trial recommendations with evidence summaries. Free, no login required. | Find trials worth discussing — ranked with evidence, not just eligibility criteria They compare it against free tools, spreadsheets and doing it manually; mixed technical confidence and budget sensitivity. Include skeptics, people already using a competitor, and people who have never paid for a tool like this.

10 fictional AI personas. Exploratory perspectives, not a survey of real customers. Methodology & limitations

Full-depth AI personas

10 personas · Use case: validation

Questions & insights

Meet the personas

Hazel Cummings

Hazel Cummings, 39, is a dedicated Oncology Nurse Navigator at a prominent regional cancer center in Houston, Texas. She earned her Master of Science in Nursing (MSN) and has spent the last seven years honing her skills in patient advocacy and clinical trial coordination. Her career choice was deeply influenced by her grandmother's own challenging experience with cancer, which highlighted the critical need for clear guidance and support through the complex healthcare system. Hazel’s current role involves a significant administrative and analytical workload; she and her one colleague are responsible for reviewing newly diagnosed breast and colorectal cancer cases weekly. This entails meticulously extracting and compiling patient summaries, a task she performs with utmost accuracy, inputting data into ClinicalTrials.gov, various sponsor portals, and a shared internal spreadsheet. This rigorous process is essential preparation for the weekly tumor board meetings where treatment plans are discussed. She and Mark, her husband, have intentionally chosen not to have children, allowing them to focus on their careers and personal growth. Hazel’s approach to her work is driven by a strong sense of responsibility and a commitment to evidence-based practice. She views her role not just as a task-doer, but as a crucial link between cutting-edge research and patients who could benefit. While her income of $92k supports a comfortable lifestyle, she remains conscious of financial planning, prioritizing long-term security over impulsive spending. The relentless pace of oncology research means she dedicates significant personal time to staying current with guidelines and advancements, often reading journals during her commute or late into the evening.

Roy Kertzmann-Maggio

Roy Kertzmann-Maggio has spent twenty years navigating the intersection of acute care and clinical research within the National Health Service. Born in the Black Country and raised in a working-class family that valued stability above all, Roy initially trained as an adult nurse, finding early fulfillment in bedside care. However, the systemic gaps he observed—patients missing out on cutting-edge treatments due to administrative inertia—pulled him toward research coordination six years ago. He holds a BSc in Adult Nursing and a postgraduate certificate in Research Methods, credentials that anchor his authority in a role demanding both medical expertise and bureaucratic fluency. Currently based at a major NHS trust in Birmingham, Roy serves as the linchpin for a specialized hematology unit. His domain is the complex world of lymphoma and myeloma trials, where the margin for error is nonexistent. His workflow is a testament to his conscientious nature: he meticulously coordinates a team of four, personally vetting every referral against a labyrinth of evolving protocols. While he utilizes 'Antidote' for initial pre-screening, the final arbiter of eligibility remains his own judgment, supported by a sprawling ecosystem of spreadsheets that he has built and maintained himself over years of incremental optimization. Roy operates with a steady, unflappable demeanor, a trait honed by decades of managing high-stakes environments. He is not driven by the allure of fame or rapid promotion but by a profound sense of duty to the public system. His income of £58,000 reflects his seniority and specialized skills, yet he lives modestly, channeling resources into his home and future security rather than conspicuous consumption. Recent decisions have focused on streamlining his team's workflow, though he remains skeptical of quick-fix solutions that lack robust validation. For Roy, the ideal outcome is not a flashy new interface, but a quieter, more reliable day where every patient record aligns perfectly with the latest scientific evidence, allowing him to focus entirely on the human element of the work.

Sina Nowak

Born and raised in a quiet town near Bonn, Sina Nowak developed an early fascination with the intricacies of the human body, particularly the nervous system, sparked by a family friend's struggle with a neurological condition. This interest propelled her towards higher education, culminating in a Master of Science in Clinical Research from a reputable German university. Her academic journey instilled a deep appreciation for scientific rigor and the ethical responsibilities inherent in medical research. Upon graduation, she secured her current position at the university hospital in Cologne, drawn by its renowned neurology department and its commitment to cutting-edge studies. Over the past five years, Sina has become an indispensable part of the team, specializing in the complex demands of MS and Parkinson's research. She thrives on the challenge of meticulously sifting through patient records, ensuring absolute precision in identifying eligible participants. Her work is characterized by a quiet determination and an unwavering commitment to accuracy, viewing each chart review as a critical step in advancing medical knowledge. She is acutely aware of the importance of patient confidentiality, handling sensitive information with the utmost discretion. While her income allows for comfortable living and consistent savings, Sina prioritizes professional development and the pursuit of knowledge over ostentatious displays of wealth. She sees her role not just as a job, but as a vital contribution to improving patient outcomes, a perspective that fuels her dedication and methodical approach to her demanding responsibilities. Her apartment, though modest, is filled with books and organized neatly, reflecting her personality. She views time as a valuable resource, meticulously planning her days to maximize efficiency and minimize administrative friction.

Shreya Marar

Shreya Marar's journey into rare disease advocacy began not by choice, but by necessity. Her son, Rohan, was diagnosed at age three with a rare genetic disorder that presented a bewildering array of symptoms and a near-complete lack of localized treatment options. This personal crisis ignited a fierce determination within her. Armed with a Master's in Social Work, Shreya leveraged her professional skills and innate empathy to navigate the complex healthcare landscape. She quickly realized the profound isolation faced by families in India dealing with similar conditions, especially those with limited English proficiency or access to global medical advancements. She founded a small, informal support group in Bengaluru, initially just a few families meeting in local parks, which has since grown into a vital online and offline community. Shreya dedicates a significant portion of her time to translating medical summaries, research papers, and clinical trial eligibility criteria from English into Hindi, ensuring critical information is accessible. She meticulously scours free resources like ClinicalTrials.gov and various rare disease registries, painstakingly cross-referencing potential trial opportunities for children in India and abroad, often spending hours compiling data into shared spreadsheets. She has never felt the need to pay for specialized trial-matching software, believing that thorough manual research and community collaboration can yield effective results. Her income of INR 12 lakh per year, combined with her husband's, is carefully managed, with a substantial portion allocated to Rohan's ongoing medical care and her advocacy efforts. Shreya’s approach is deeply practical; she prioritizes tangible support and actionable information, driven by the belief that persistence and shared knowledge can make a tangible difference in the lives of families facing rare diseases. Her recent focus has been on building bridges between Indian families and international research institutions, a challenging but rewarding endeavor that consumes much of her waking hours.

Vicki MacGyver

Vicki MacGyver, 52, has carved out a niche as an independent oncology care manager in Phoenix, Arizona, a role she embraced after a decade in hospital-based oncology navigation. Her journey began with a BS in Health Administration, followed by years of hands-on experience that revealed a critical gap: personalized, dedicated support for patients navigating the labyrinthine world of cancer treatment and clinical trials. Frustrated by the systemic limitations and the sheer volume of information patients had to process alone, she decided to leverage her expertise independently. She established her practice five years ago, focusing on providing comprehensive referral coordination and patient advocacy. Vicki operates from a home office, managing a caseload of roughly ten clients at any given time. Her operational backbone consists of Airtable for robust client management and detailed spreadsheets where she meticulously tracks patient histories, referral pathways, and trial eligibility criteria against data pulled from public registries like ClinicalTrials.gov. This methodical approach is crucial, as she often reviews extensive medical records before even speaking with a patient's family. Her income of approximately $78,000 annually reflects her specialized skills and the demanding nature of her work. Vicki is driven by a deep-seated need for order and a commitment to responsiveness, ensuring her clients feel supported and informed. She values her independence immensely, relishing the autonomy her self-employment provides. This autonomy allows her to dedicate the necessary time to each case, a stark contrast to the often-rushed environment of larger institutions. Recently, she's been exploring new digital tools to streamline her data analysis, seeking ways to more efficiently cross-reference patient profiles with the ever-expanding universe of oncology trials. She made a conscious decision last quarter to invest in a more robust cloud storage solution to better manage the growing volume of patient data securely, reflecting her commitment to both efficiency and discretion. Her personal life is deliberately kept separate, with evenings and weekends reserved for decompressing, pursuing hobbies like knitting, and maintaining connections with her adult children and a small circle of close friends. She views her work not just as a profession, but as a vital service, driven by a pragmatic desire to bring clarity and hope to individuals facing immense uncertainty.

Lowell Heidenreich

Dr. Lowell Heidenreich has dedicated over two decades to the field of haematology, establishing himself as a respected consultant within both the National Health Service and the private sector in London. His journey began with a solid foundation in general medicine, culminating in specialist training in haematology, marked by his MRCP qualification. He chose a career path that allows for deep patient engagement, splitting his time between busy NHS outpatient clinics, where he manages a broad spectrum of haematological conditions, and a small, discreet private practice in Kensington. This dual role reflects his commitment to providing continuity of care, seeing patients through complex treatment pathways. His particular focus lies in lymphoid malignancies, specifically lymphoma and myeloma, areas where clinical trial participation can offer significant hope and novel therapeutic avenues. Lowell approaches patient care with an almost academic rigour, driven by a profound belief in evidence-based medicine and meticulous clinical judgment. He is known for his thoroughness, spending considerable time ensuring patients understand their options, including the intricate details of clinical trial eligibility. His current practice involves fielding numerous patient-initiated questions about trials, a process that often requires him to consult the trust’s internal trial lists and then resort to manual searches on ClinicalTrials.gov. This manual approach, while yielding results, consumes a significant portion of his valuable time, a friction point he navigates with quiet determination. He is a man of routine and order, valuing professional reputation and the trust his patients place in him above all else. His income reflects his experience and the demands of his dual roles, allowing for a comfortable, albeit not extravagant, lifestyle. He is deeply invested in the long-term health outcomes of his patients, viewing each case as a complex puzzle requiring careful, systematic analysis and a steadfast adherence to the highest professional standards. His recent decision to continue relying on manual trial searches, despite the time cost, stems from a deep-seated preference for direct control and a cautious skepticism towards overly automated solutions, prioritising his own verification process.

Irène Schneider

Irène Schneider, 48, is a dedicated hospital social worker and patient navigator based in Lyon, France. Holding a Licence en travail social, she has dedicated the last twelve years to navigating the complex healthcare system for patients, with a particular focus on oncology. She works at a patient-navigation desk within a large hospital network, collaborating closely with two colleagues. Her role is critical: she meticulously analyzes patient discharge letters, extracting vital information to identify individuals who might benefit from open clinical study options. This requires a deep understanding of medical terminology, research protocols, and the specific inclusion/exclusion criteria for numerous trials. She acts as a vital conduit, coordinating with research nurses across two different hospital sites to ensure seamless communication and patient management. Irène lives alone in a comfortable apartment in Lyon's 7th arrondissement, maintaining a structured personal life that balances her demanding professional commitments with quiet evenings, weekend market visits, and time spent with a small circle of close friends. Her income of EUR 46k/year reflects her experience and the specialized nature of her role, allowing for a comfortable but not extravagant lifestyle. She is driven by a strong sense of empathy and a commitment to patient advocacy, valuing clear communication and ensuring equitable access to potentially life-saving research opportunities. Recent decisions in her work life have focused on streamlining the documentation review process, implementing a shared digital checklist with her colleagues to reduce errors and improve efficiency in identifying eligible patients for oncology trials. She is deeply committed to the principle of confidentiality, understanding the sensitive nature of the information she handles daily. Her approach is characterized by meticulousness and a calm demeanor, even when faced with the emotional intensity of her patients' situations or the administrative hurdles of the healthcare system.

Shirley Abernathy

Shirley Abernathy's life trajectory shifted dramatically at age 31 when her youngest son, Leo, was diagnosed with Duchenne muscular dystrophy (DMD). A former marketing coordinator with a BA in Psychology, she transitioned into a full-time caregiver and patient advocate, a role she has embraced with fierce dedication for the past five years. Her Newark, New Jersey home is the hub of Leo's care, a place where medical schedules, therapy equipment, and research binders coexist. Her household income of $110,000, primarily from her husband Mark's software engineering career, is carefully managed to cover Leo's extensive medical needs, including specialized therapies and travel to leading treatment centers. Shirley's days are consumed by Leo's care, but her 'work' extends far beyond the physical demands. She has become an expert navigator of the complex landscape of pediatric neuromuscular trials. Her research process is rigorous: she subscribes to multiple mailing lists, actively participates in private Facebook groups for DMD parents, and meticulously monitors ClinicalTrials.gov, often setting up custom alerts. She spends hours synthesizing information, identifying potential trial eligibility criteria, and formulating precise questions for Leo's specialist appointments. This deep dive into clinical research methodology stems from a profound desire for transparency and a need to feel in control amidst the uncertainty of Leo's condition. She views herself as Leo's primary defender, ensuring he receives the best possible care and access to cutting-edge treatments. Her background in psychology informs her empathetic approach to connecting with other families and her understanding of the emotional toll of chronic illness. She is driven by a powerful sense of responsibility and a commitment to family stability, constantly balancing the immediate demands of Leo's health with the long-term goal of maximizing his quality of life. Her personal time is scarce, often sacrificed for Leo's needs, but she cherishes the rare moments of respite with her husband and older daughter, recognizing the importance of maintaining family equilibrium. Shirley is not motivated by status or material wealth; her currency is knowledge, progress, and hope for Leo's future.

Dandapaani Pandey

Dandapaani Pandey's journey into clinical research coordination began not from a burning passion for science, but from a pragmatic desire for a stable, respected career that contributed meaningfully to society. Growing up in a middle-class family in Hyderabad, he witnessed firsthand the anxieties and complexities families faced navigating healthcare systems, especially during serious illnesses. This observation, coupled with a natural inclination towards order and detail, steered him towards a Master's in Clinical Research. He interned at a large hospital before finding his current role at a busy private oncology practice. His four years in this position have solidified his reputation for meticulousness. He manages a manual system for tracking open solid-tumor studies, a critical but labor-intensive task. Dandapaani understands the immense pressure on the six oncologists he supports; his primary focus is to be an unfailing point of accuracy and efficiency in the trial referral process. He often finds himself explaining complex protocol eligibility criteria to distressed families, a task he approaches with both professional diligence and genuine empathy. His income of INR 9 lakh per year allows him to comfortably support his wife and contribute to his joint family’s household expenses, with a keen eye on future savings. He is currently grappling with the sheer manual effort required to keep his trial database current and accurate, recognizing the potential for faster, more precise methods, but bound by the existing clinic infrastructure and his conservative approach to adopting new systems without overwhelming proof of benefit and ease of integration.

Luca Kok

Luca Kok is a 29-year-old Patient-access associate operating at the nerve center of a lean, 12-person rare disease startup in Amsterdam. With an MSc in Biomedical Sciences, he possesses the technical acumen to dissect complex medical records alongside the operational grit required to navigate the chaotic landscape of early-access programs. Since joining the company eighteen months ago, Luca has been instrumental in transforming a disorganized influx of patient referrals into a semi-structured pipeline, though the transition has been fraught with friction. He currently manages the triage for an innovative therapy targeting ultra-rare metabolic disorders, a role that demands he be part detective, part ethicist, and part project manager. His daily reality involves wrestling with the limitations of current technology; while he utilizes TrialJectory for its database breadth, he finds himself constantly bridging gaps with custom-built spreadsheets to account for the idiosyncratic nature of rare disease patient histories. This hybrid approach, born of necessity, has made him deeply skeptical of 'plug-and-play' solutions that promise to solve problems they don't fully understand. Luca is driven by a profound sense of mission; he knows that every hour saved in triage could mean a month earlier for a patient on a waiting list. However, this drive is tempered by a realistic appreciation for the bottlenecks of the industry. He is financially stable, earning a solid EUR 54k, but views his income as a means to secure a future where he can advocate for better systemic infrastructure in clinical research. Recently, he spearheaded a initiative to standardize incoming data formats, a move that required navigating resistance from impatient external partners. Despite the pressures, Luca remains optimistic, believing that the intersection of rigorous data management and compassionate care is where the future of rare disease treatment lies.

Want a panel built for your exact market?

Create your own audience